Compound profile
DSIP (Delta Sleep-Inducing Peptide)
EmergingAlso known as: Delta Sleep-Inducing Peptide · WAGGDASGE nonapeptide
A nonapeptide isolated from rabbit cerebral venous blood in the 1970s and named for its apparent sleep-promoting effect in early animal work. One of the oldest "sleep peptides" discussed online, though its own reviewers call its biological role "a still unresolved riddle."
Overview
Delta sleep-inducing peptide, almost always shortened to DSIP, is a small nonapeptide, meaning a chain of nine amino acids, first isolated from the blood of rabbits in the 1970s. Its name comes from the effect researchers reported when they first tested it: increased delta wave activity on EEG recordings, the slow brain waves characteristic of deep sleep.
The peptide's origin story is distinctive. Researchers Schoenenberger and Monnier in Basel were studying sleep by electrically stimulating a sleep-related area of the rabbit brain and then collecting blood draining from that region. When they infused that collected blood into the brain ventricles of awake rabbits, the animals showed EEG patterns resembling natural sleep. They eventually isolated and sequenced the specific peptide responsible, publishing the amino acid sequence in the late 1970s and naming it for the effect they had observed.
DSIP is one of the oldest sleep peptides still discussed today, but its own research community has never fully settled what it is or how it works. A widely cited 2006 review of the field described DSIP's role as a genuine sleep factor as a still unresolved riddle, a striking admission decades after its initial discovery, and that uncertainty is the honest starting point for understanding where the science currently stands.
Mechanism (plain language)
Proposed to modulate adrenergic transmission and circadian/neuroendocrine signaling, but no confirmed DSIP receptor or gene has ever been isolated, a notable gap compared with better-characterized sleep-regulating hormones.
How it works
DSIP is proposed to act on adrenergic signaling, the neurotransmitter system involving adrenaline and noradrenaline, and on broader circadian and neuroendocrine regulation, but this remains a proposed mechanism rather than a confirmed one. The single biggest gap in DSIP's biology is that, unlike most peptide hormones discussed on this site, no dedicated DSIP receptor or gene has ever been definitively isolated or confirmed, decades after its initial discovery. That is unusual and worth sitting with: most other sleep- and hormone-regulating peptides have at least an identified receptor even when their downstream effects are still debated, and DSIP does not clearly have that.
The original animal experiments that led to DSIP's discovery and naming, cross-circulation studies where blood from sleeping rabbits was infused into awake rabbits, did produce measurable increases in delta wave activity, and synthetic DSIP given at comparable doses reproduced that effect in follow-up work. But without a confirmed receptor, it is difficult to say precisely how that effect is being produced at a molecular level, which is why more recent reviews describe DSIP's mechanism, and even its basic status as a genuine physiological sleep factor, as unresolved.
What research suggests
Small, older human studies using intravenous DSIP report sleep induction and normalization of disturbed sleep in patients with insomnia, plus reported effects on daytime alertness and stress tolerance. These are decades-old, small, and largely from one or two research groups.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Sleep induction in early animal work
The original rabbit cross-circulation experiments and subsequent synthetic DSIP dosing reported increased delta wave (deep sleep) activity on EEG.
Normalized sleep in small human studies
An older open study of insomnia patients receiving a series of DSIP injections reported normalized sleep patterns.
Reported effects on stress tolerance
Some of the older human literature describes effects on daytime alertness and stress tolerance alongside sleep changes, though these come from the same small, dated body of work.
Long research history
DSIP has decades of accumulated laboratory interest, meaning there is a reasonably large older literature to draw on even though it has not been followed up with modern, rigorous trials.
Uncertainties & risks
A dedicated review explicitly frames the sleep-factor hypothesis for DSIP as "extremely poorly documented and still weak," since no DSIP gene, protein, or receptor has been confirmed. No modern, large, placebo-controlled human trials exist, and it is not an approved sleep therapeutic.
The honest summary of DSIP's evidence base is that it is old, small, and has not been meaningfully extended by modern research. The human trials that exist, including the open study of insomnia patients from the 1980s, involved very small numbers of participants, were not always blinded or placebo-controlled by current standards, and came largely from one or two research groups working in the same era. No modern, large, placebo-controlled human trial of DSIP for sleep exists. Perhaps most importantly, the field itself has not resolved whether DSIP is a genuine, biologically confirmed sleep factor at all. A dedicated 2006 review concluded that the evidence supporting its role as a sleep-inducing hormone is extremely poorly documented and still weak, and the absence of any confirmed receptor or gene decades after discovery reinforces that caution. DSIP is not an approved sleep therapeutic anywhere, and current interest in it as a research or biohacking compound runs well ahead of what has actually been demonstrated.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.